ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Mechanism and Experimental Verification of Luteolin for the Treatment of Osteoporosis Based on Network Pharmacology

Liang, Guihong; Zhao, Jinlong; Dou, Yaoxing; Yang, Yuan; Zhao, Di; Zhou, Zhanpeng; Zhang, Rui; Yang, Weiyi*; Zeng, Lingfeng*广州中医药大学
Frontiers in Endocrinology2022-3-8DOI: 10.3389/fendo.2022.866641
9被引5阅读
引用收藏
分享

摘要

PurposeTo explore the molecular mechanism of luteolin in the treatment of osteoporosis (OP) by network pharmacological prediction and experimentation. MethodsThe target proteins of luteolin were obtained with the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). OP-related proteins were extracted from the Comparative Toxicogenomics Database (CTD) and GeneCards and DisGeNET databases. We imported the common protein targets of luteolin and OP into the STRING database to obtain the relationships between the targets. The common target proteins of luteolin and OP were assessed by KEGG and GO enrichment analyses with the DAVID database. Animal experiments were conducted to verify the effect of luteolin on bone mineral density in ovariectomised (OVX) rats. Finally, the effects of luteolin on key signalling pathways were verified by cell experiments in vitro. ResultsForty-four targets of luteolin involved in the treatment of OP, including key target proteins such as TP53, AKT1, HSP90AA1, JUN, RELA, CASP3, and MAPK1, were screened. KEGG enrichment analysis found that luteolin inhibits OP by regulating the PI3K-Akt, TNF, oestrogen and p53 signalling pathways. The results of animal experiments showed that bone mass in the low-dose luteolin group (Luteolin-L group, 10 mg/kg), high-dose luteolin group (Luteolin-H group, 50 mg/kg) and positive drug group was significantly higher than that in the OVX group (P<0.05). Western blot (WB) analysis showed that the protein expression levels of Collagen I, Osteopontin and RUNX2 in bone marrow mesenchymal stem cells (BMSCs) cultured with 0.5, 1 and 5 mu M luteolin for 48 h were significantly higher than those in the dimethyl sulfoxide (DMSO) group (P<0.05). In vitro cell experiments showed that the p-PI3K/PI3K and p-Akt/Akt expression ratios in BMSCs cultured with 0.5, 1 and 5 mu M luteolin for 48 h were also significantly higher than those in the DMSO group (P<0.05). ConclusionsLuteolin has multitarget and multichannel effects in the treatment of OP. Luteolin could reduce bone loss in OVX rats, which may be due to its ability to promote the osteogenic differentiation of BMSCs by regulating the activity of the PI3K-Akt signalling pathway.

学科与关键词

关键词
Traditional Chinese medicineluteolinosteoporosisnetwork pharmacologysignalling pathwayexperimental verification
相关
加载中…
  • Network pharmacology and experimental verification-based strategy for exploring the mechanisms of luteolin in the treatment of osteosarcoma
    Huang, Renxuan; Xu, Mingxian; Guo, Weitang; Cheng, Mingzhe; Dong, Rui; Tu, Jian; Xu, Shao*; Zou, Changye*Cancer Cell International, 2023, 23(1): 213.被引 1
  • The potential mechanism of Fructus Ligustri Lucidi promoting osteogenetic differentiation of bone marrow mesenchymal stem cells based on network pharmacology, molecular docking and experimental identification
    Kong, Yuanhang; Ma, Xinnan; Zhang, Xin; Wu, Leilei; Chen, Dechun; Su, Bo; Liu, Daqian; Wang, Xintao*Bioengineered, 2022, 13(4): 10640-10653.被引 5
  • Network pharmacology identifies fisetin as a treatment for osteoporosis that activates the Wnt/&beta;-catenin signaling pathway in BMSCs
    Liang, Guihong; Zhao, Jinlong; Pan, Jianke; Yang, Yuan; Dou, Yaoxing; Yang, Weiyi; Zeng, Lingfeng*; Liu, Jun*Journal of Orthopaedic Surgery and Research, 2023, 18(1): 312.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Endocrinology
发表日期
2022-03-08
卷期
第 13 卷
页码
866641
DOI
10.3389/fendo.2022.866641
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82004383, 81974574]; National key research and development program [2021YFC1712804]; Project of Administration of Traditional Chinese Medicine of Guangdong Province [20201129, 20225016, 20225025]; Project of Guangdong Provincial Department of Finance [[2014]157]; Medical Science Research Foundation of Guangdong Province [A2020105, B2019091]; Science and Technology Planning Project of Guangzhou [202102010273]; Science and Technology Research Project of Guangdong Provincial Hospital of Chinese Medicine [YN2019ML08]

作者

  • L

    Liang, Guihong (第一作者)

    2 · guangzhou univ chinese med

  • Z

    Zhao, Jinlong

    2 · guangzhou univ chinese med

查看全部 9 位作者收起作者
  • D

    Dou, Yaoxing

    2 · guangzhou univ chinese med

  • Y

    Yang, Yuan

    2 · guangzhou univ chinese med

  • Z

    Zhao, Di

    2 · guangzhou univ chinese med

  • Z

    Zhou, Zhanpeng

    guangzhou univ chinese med

  • Z

    Zhang, Rui

    guangzhou univ chinese med

  • Y

    Yang, Weiyi (通讯)

    2 · guangzhou univ chinese med

  • Z

    Zeng, Lingfeng (通讯)

    2 · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417